Repros to drop testosterone drug in U.S. if key study fails
0
(Reuters) - Repros Therapeutics Inc will abandon efforts to seek approval for its testosterone drug in the United States if an ongoing study fails, and shift focus to its uterine fibroids drug that showed promise in a mid-stage trial.